0.22
+0.0093(+4.45%)
Currency In USD
| Previous Close | 0.21 |
| Open | 0.23 |
| Day High | 0.25 |
| Day Low | 0.21 |
| 52-Week High | 1.53 |
| 52-Week Low | 0.13 |
| Volume | 37.36M |
| Average Volume | 6.96M |
| Market Cap | 10.64M |
| PE | -0.16 |
| EPS | -1.33 |
| Moving Average 50 Days | 0.22 |
| Moving Average 200 Days | 0.34 |
| Change | 0.01 |
If you invested $1000 in Mustang Bio, Inc. (MBIO) since IPO date, it would be worth $1.48 as of January 05, 2025 at a share price of $0.218. Whereas If you bought $1000 worth of Mustang Bio, Inc. (MBIO) shares 5 years ago, it would be worth $3.57 as of January 05, 2025 at a share price of $0.218.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mustang Bio Receives Positive Listing Determination from Nasdaq
GlobeNewswire Inc.
Nov 12, 2024 1:30 PM GMT
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cure
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
GlobeNewswire Inc.
Nov 07, 2024 1:30 PM GMT
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1 oncolytic virus) and MB-101 (IL13Rα2‐targeted CAR-T ce
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
GlobeNewswire Inc.
Oct 24, 2024 6:10 PM GMT
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cure